Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects
NCT04772365 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 1, 2021
- Completion date
- December 10, 2021
- Enrollment
- 52 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.